Depo-Provera Warning Label Gap: How US Women Were Left Unwarned While Other Countries Acted

The Meningioma Risk That Pfizer Knew About

Meningiomas are brain tumors arising from the meninges — the membranes covering the brain and spinal cord. While typically classified as benign, meningiomas can cause debilitating symptoms including seizures, vision loss, hearing loss, and cognitive impairment, and treatment often requires brain surgery with significant risks and a lengthy recovery. A growing body of evidence links long-term use of progestins, including medroxyprogesterone acetate (the active ingredient in Depo-Provera), to a significantly elevated risk of meningioma. The critical question in ongoing litigation is not whether the risk exists — the scientific evidence is now clear and has been accepted by multiple international regulatory agencies — but why American women were never adequately warned. Depo-Provera has been on the U.S. market since 1992 as an injectable contraceptive administered every three months. Over 30 years, millions of American women have used the product, many for extended periods spanning years or even decades. The progestin-meningioma link has been suspected since at least the early 2000s based on biological plausibility — meningiomas are known to express progesterone receptors, making them responsive to exogenous progestin hormones — and accumulating case reports in the medical literature.

France Sounded the Alarm in 2020

In June 2020, the French National Agency for the Safety of Medicines (ANSM) issued a formal alert linking injectable medroxyprogesterone acetate to an increased risk of meningioma. This followed a large French epidemiological study that analyzed over 1.8 million women and found a 3.49-fold increased risk of intracranial meningioma among women who had used injectable medroxyprogesterone acetate for more than one year. The magnitude of this risk — nearly three and a half times the baseline rate — is comparable to or greater than risks that have prompted black box warnings for other medications in the United States. The ANSM required new prescribing restrictions: Depo-Provera should only be used when other contraceptive methods are unsuitable, patients must be explicitly informed of the meningioma risk before starting treatment, and treatment should be stopped immediately if a meningioma is diagnosed. France also recommended MRI screening for women who had used the product long-term, a precautionary measure reflecting the seriousness of the finding. These actions were not taken lightly — they followed rigorous review by French pharmacovigilance authorities and were based on peer-reviewed epidemiological evidence published in major medical journals.

Other Countries Followed — The US Did Not

After France's regulatory action, other national drug safety agencies reviewed their own data and reached similar conclusions. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) updated safety information in 2022, informing healthcare professionals of the meningioma risk and recommending monitoring for long-term users. The European Medicines Agency (EMA) issued an updated safety assessment requiring product information changes across EU member states. Australia's Therapeutic Goods Administration (TGA) updated the consumer medicine information for Depo-Provera in 2023 to include meningioma as a potential adverse effect. Health Canada initiated a formal safety review in 2023 and issued a safety communication to healthcare professionals. In each case, the regulatory agencies independently concluded that the weight of evidence justified warning healthcare providers and patients about the brain tumor risk associated with long-term use. The United States FDA has not taken comparable action. As of February 2026, the Depo-Provera US prescribing label does not contain a black box warning about meningioma. The patient medication guide does not clearly warn about brain tumor risk. American women and their physicians are making treatment decisions without access to the same safety information available to women in France, the United Kingdom, Australia, and throughout the European Union.

What the Science Shows

The French study that prompted the ANSM's 2020 action was not an isolated finding. Multiple peer-reviewed studies have documented the association between progestins and meningioma, building a consistent body of evidence across different populations and study designs. A 2021 BMJ study analyzing 1.8 million French women confirmed a clear dose-response relationship: longer duration of use corresponds to higher risk, with women using injectable medroxyprogesterone acetate for more than three years facing a risk approximately five to seven times the baseline rate. A 2022 Lancet study extended these findings across multiple progestin formulations, demonstrating that the meningioma risk is not unique to Depo-Provera but is particularly pronounced with injectable medroxyprogesterone acetate due to its high progestin dose and sustained systemic exposure. The biological mechanism is well-characterized. Meningiomas express progesterone receptors at high rates — approximately 70 percent of meningiomas are progesterone-receptor positive. Exogenous progestins bind to these receptors and stimulate tumor cell proliferation. This is not a speculative hypothesis but an established molecular pathway documented in neuro-oncology literature spanning decades. Pfizer's internal pharmacovigilance data and post-marketing surveillance reports would have captured meningioma adverse event reports for years, potentially decades. The company's failure to voluntarily update the US prescribing label with a meningioma warning — even after France and other countries required one — is central to plaintiffs' claims.

Why This Matters for US Women Filing Lawsuits

The international regulatory timeline is the most powerful evidence in Depo-Provera failure-to-warn litigation. It demonstrates that the scientific evidence was strong enough to prompt regulatory action in multiple countries years before any comparable US warning was issued. Under US product liability law, a manufacturer has a duty to warn about known or reasonably knowable risks. When France required meningioma warnings in 2020 based on published epidemiological data available to any pharmaceutical company with a pharmacovigilance department, that risk was unquestionably 'reasonably knowable' to Pfizer. The company's failure to voluntarily update the US label — and the FDA's failure to require it through a labeling supplement or safety communication — left millions of American women uninformed about a serious risk to which they were actively being exposed with each quarterly injection. For women who developed meningiomas after long-term Depo-Provera use, the regulatory gap documented in this analysis forms the factual foundation of their failure-to-warn claims. Had they been warned — as women in France, the UK, and Australia were — they could have made an informed choice to use alternative contraception. Instead, that choice was taken from them by a manufacturer that knew or should have known about the risk and a regulatory system that failed to act with the urgency the evidence demanded.